logobeta
본 영문본은 리걸엔진의 AI 번역 엔진으로 번역되었습니다. 수정이 필요한 부분이 있는 경우 피드백 부탁드립니다.
텍스트 조절
arrow
arrow
(영문) 부산지방법원 2014.10.23 2014고정4009
약사법위반등
Text

Defendant shall be punished by a fine of KRW 700,000.

Where the defendant fails to pay the above fine, one hundred thousand won shall be one day.

Reasons

Punishment of the crime

1. No trademark identical with the registered trademark of another person in violation of the Trademark Act shall be used for goods similar to the designated goods, or any trademark similar to the registered trademark of another person shall be used for goods identical with

Nevertheless, from June 2012 to July 10, 2014, the Defendant purchased letters similar to those of the letters (VGR 100) written on the front side of the “Non-Agrogra’s product,” a trademark right holder, from the beginning point of Busan Dong-dong from the Busan taxi platform, to the front side of the “Agrogra,” a product of the U.S. owner of the trademark right, and sold the remainder of the 48 million U.S. vehicle and the 480 million U.S. vehicle and the 314.4 million U.S. vehicle and the 341.4 million U.S. vehicle and the 34.4.4 million U.S. vehicle and the 34.4.24 million U.S. vehicle and the 4.4.24.24.0 million U.S. vehicle and the 31.4.

2. Unless a pharmacy founder or a person who established a pharmacy in violation of the Pharmaceutical Affairs Act is unable to sell or obtain drugs for the purpose of selling them, such as the statement in paragraph (1), acquired from a man with no name the “non-agra and Simalce” the drugs, and sold them to the unspecified number of customers and kept them for the purpose of selling the remainder of 65 years.

Summary of Evidence

1. Defendant's legal statement;

1. The police statement concerning B;

1. Request for appraisal, notification of seizure, and original trademark register;

1. Application of the Acts and subordinate statutes to photographs related to seizure, such as photographs of street posts;

1. Medicines under Article 93 of the relevant Act as to facts constituting an offense, Article 93 of the selective Trademark Act, and Articles 93 (1) 7 and 44 (1) of the Pharmaceutical Affairs Act;

arrow